John Bason, Ph.D., is the Chief Executive Officer, and President of the Management Board at nCage Therapeutics. John is also a Co-Founder at nCage. John previously served as a consultant to the Polish Development Fund (PFR), and has Board-level experience in various Polish companies, additionally experience in investing in different Biotech’s.

John brings to nCage a significant background of research and development experience having worked as a Senior Investigative Scientist at the Medical Research Laboratory (MRC) in Cambridge, United Kingdom, where he was responsible for leading a series of collaborative research projects. John’s research concerned deducing the structure and mechanism of the ATP Synthase and involved a network of international scientists in North America. John also has extensive commercial project management experience in high technology sectors in Poland and abroad.

John received his Ph.D. from Hughes Hall College, University of Cambridge, and his MBioc., in Molecular and Cellular Biochemistry from St. Hugh’s College, University of Oxford, United Kingdom.

Christopher Kaplan is the Chief Business Officer and Member of the Management Board of nCage Therapeutics. Chris has over 30 years of experience in the global life science industry in the development and commercialization of new therapies and technologies. Chris is also the President of Axcend Health, a biotechnology venture-building firm with offices in Boston and Warsaw.

Chris has a substantial background of experience in global life science operations, business development and licensing, and has executed numerous partnering and acquisition transactions. Chris has held significant senior global leadership roles at Bristol- Myers Squibb, Novartis, Boehringer Ingelheim and Sanofi.

Chris holds a Masters of Science Degree from the University of Pennsylvania, a Bachelors Degree from Columbia University, and a Management degree from the Institut Européen d’Administration des Affaires (INSEAD)

Jonathan Heddle, Ph.D., DSc., Is a Co-Founder and Chief Scientific Officer at nCage Therapeutics, and leads the company’s research and development activities focused on design of novel protein structures and therapeutics. Jonathan also serves as an Extraordinary Professor at the Malopolska Centre of Biotechnology (MCB), at Jagiellonian University in Krakow. Jonathan has >20 years of experience in researching natural and artificial bio-nanomachines. He has made significant contributions to the understanding of DNA gyrase an important antibacterial target, and has played a major role in designing novel artificial structures from DNA and proteins including nanorobotic DNA boxes, protein nanotubes and protein cages.

Prior to nCage and MCB, Jonathan carried out research at the John Innes Centre, UK and spent over a decade in Japan where he was engaged in academic teaching and investigational research, and responsible for laboratories at Tokyo Institute of Technology, and RIKEN, Japan’s largest scientific research institution.

Jonathan received his DSc. from the Institute of Biochemistry and Biophysics, Polish Academy of Sciences, his Ph.D. in Biochemistry from the University of Leicester, and a B.Pharma (Hons) from the University of Nottingham, United Kingdom. Jonathan is currently Professor in the Department of Biosciences at Durham University.